- Press Release -

Rockville, Md. The global kidney cancer diagnostics market is set to expand at a 6.4% CAGR through 2022, according to Fact.MR, as the management and diagnosis of renal cell carcinoma changes quickly. Work in active surveillance, renal biopsy and minimally invasive thermal ablation, prompted by rising detection of small renal masses in higher-risk patients, is broadening how the disease is caught and tracked.

Immunochemistry testing leads by type, hospital-associated labs handle most of the work, and North America carries the market. Because kidney cancer most often affects older patients, diagnosis is complex, and clinicians are pressing for more effective tests beyond the MRI and CT scans that remain standard.

Tests, Settings and Regions

Immunochemistry tests are the most sought-after and are expected to reach US$ 351.8 Mn by 2022 at the highest CAGR, followed by complete blood count. Urine analysis is the second most lucrative approach, while blood chemistry tests stay comparatively small. By setting, hospital-associated labs generate the largest revenue, independent diagnostic laboratories rank second, and cancer research institutes grow the quickest.

North America accounts for the largest revenue, followed by Europe, which expands at a higher rate than North America, while Asia Pacific excluding Japan is the fastest-growing region overall.

R&D Reshapes Detection

The push here comes from research. Medical organisations are directing heavy investment into new diagnostic procedures, and early-detection improvements have translated into real gains for test makers. Several are partnering with research bodies to develop methods that can also slow how quickly tumours mature between stages, tightening the link between diagnosis and treatment.

Suppliers and Their Playbook

The field brings together molecular diagnostics specialists and laboratory majors.

• NeoGenomics Laboratories, Myriad Genetics Inc, NanoString Technologies Inc., Rosetta Genomics, Sysmex Corporation, Illumina, Inc., Roche Holding AG, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., and Abbott Laboratories are among the key players in the report.

Reading the Market for Decisions

For diagnostics firms, immunochemistry and early-detection methods mark where to invest. Investors get a market with a steady clinical tailwind. Procurement and lab teams can plan around hospital labs leading demand, immunochemistry carrying volume, and Asia Pacific offering the fastest growth through 2022.

About the Report

Fact.MR's study covers the global kidney cancer diagnostics market for the 2017 to 2022 forecast period, with segmentation by test type, end user and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the kidney cancer diagnostics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.